File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1476-5381.1992.tb12755.x
- Scopus: eid_2-s2.0-0026760157
- PMID: 1422587
- WOS: WOS:A1992JQ85600019
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Calmodulin antagonists inhibit endothelium-dependent hyperpolarization in the canine coronary artery
Title | Calmodulin antagonists inhibit endothelium-dependent hyperpolarization in the canine coronary artery |
---|---|
Authors | |
Keywords | A23187 bradykinin calcium calmidazolium endothelium‐derived hyperpolarizing factor (EDHF) fendiline lemakalim |
Issue Date | 1992 |
Publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1 |
Citation | British Journal Of Pharmacology, 1992, v. 107 n. 2, p. 382-386 How to Cite? |
Abstract | 1. The effects of the calmodulin antagonists, calmidazolium and fendiline were investigated on endothelium-dependent hyperpolarization in the canine coronary artery. The membrane potential of vascular smooth muscle cells was measured with the microelectrode technique. 2. Smooth muscle cells of the canine coronary artery had a resting membrane potential of -50 mV. Bradykinin and the Ca2+-ionophore, A23187, induced concentration- and endothelium-dependent hyperpolarization. The hyperpolarization induced by a supramaximal concentration of bradykinin (10-6 M) reached approximately 20 mV. 3. Calmidazolium (10-5 M) and fendiline (10-4 M) inhibited hyperpolarization induced by bradykinin and A23187. By contrast, calmidazolium did not affect the hyperpolarization induced by lemakalim, an opener of ATP-sensitive K+-channels. 4. These observations suggest that calmodulin is involved in the generation of endothelium-dependent membrane hyperpolarization of vascular smooth muscle. |
Persistent Identifier | http://hdl.handle.net/10722/171073 |
ISSN | 2023 Impact Factor: 6.8 2023 SCImago Journal Rankings: 2.119 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nagao, T | en_US |
dc.contributor.author | Illiano, S | en_US |
dc.contributor.author | Vanhoutte, PM | en_US |
dc.date.accessioned | 2012-10-30T06:12:05Z | - |
dc.date.available | 2012-10-30T06:12:05Z | - |
dc.date.issued | 1992 | en_US |
dc.identifier.citation | British Journal Of Pharmacology, 1992, v. 107 n. 2, p. 382-386 | en_US |
dc.identifier.issn | 0007-1188 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171073 | - |
dc.description.abstract | 1. The effects of the calmodulin antagonists, calmidazolium and fendiline were investigated on endothelium-dependent hyperpolarization in the canine coronary artery. The membrane potential of vascular smooth muscle cells was measured with the microelectrode technique. 2. Smooth muscle cells of the canine coronary artery had a resting membrane potential of -50 mV. Bradykinin and the Ca2+-ionophore, A23187, induced concentration- and endothelium-dependent hyperpolarization. The hyperpolarization induced by a supramaximal concentration of bradykinin (10-6 M) reached approximately 20 mV. 3. Calmidazolium (10-5 M) and fendiline (10-4 M) inhibited hyperpolarization induced by bradykinin and A23187. By contrast, calmidazolium did not affect the hyperpolarization induced by lemakalim, an opener of ATP-sensitive K+-channels. 4. These observations suggest that calmodulin is involved in the generation of endothelium-dependent membrane hyperpolarization of vascular smooth muscle. | en_US |
dc.language | eng | en_US |
dc.publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1 | en_US |
dc.relation.ispartof | British Journal of Pharmacology | en_US |
dc.subject | A23187 | - |
dc.subject | bradykinin | - |
dc.subject | calcium | - |
dc.subject | calmidazolium | - |
dc.subject | endothelium‐derived hyperpolarizing factor (EDHF) | - |
dc.subject | fendiline | - |
dc.subject | lemakalim | - |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Benzopyrans - Pharmacology | en_US |
dc.subject.mesh | Bradykinin - Pharmacology | en_US |
dc.subject.mesh | Calcimycin - Pharmacology | en_US |
dc.subject.mesh | Calmodulin - Antagonists & Inhibitors | en_US |
dc.subject.mesh | Coronary Vessels - Drug Effects - Physiology | en_US |
dc.subject.mesh | Cromakalim | en_US |
dc.subject.mesh | Dogs | en_US |
dc.subject.mesh | Endothelium, Vascular - Physiology | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Fendiline - Pharmacology | en_US |
dc.subject.mesh | Imidazoles - Pharmacology | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Membrane Potentials - Drug Effects | en_US |
dc.subject.mesh | Muscle, Smooth, Vascular - Drug Effects - Physiology | en_US |
dc.subject.mesh | Potassium Channels - Drug Effects | en_US |
dc.subject.mesh | Pyrroles - Pharmacology | en_US |
dc.title | Calmodulin antagonists inhibit endothelium-dependent hyperpolarization in the canine coronary artery | en_US |
dc.type | Article | en_US |
dc.identifier.email | Vanhoutte, PM:vanhoutt@hku.hk | en_US |
dc.identifier.authority | Vanhoutte, PM=rp00238 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1111/j.1476-5381.1992.tb12755.x | - |
dc.identifier.pmid | 1422587 | - |
dc.identifier.scopus | eid_2-s2.0-0026760157 | en_US |
dc.identifier.volume | 107 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.spage | 382 | en_US |
dc.identifier.epage | 386 | en_US |
dc.identifier.isi | WOS:A1992JQ85600019 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Nagao, T=7401489430 | en_US |
dc.identifier.scopusauthorid | Illiano, S=6602119848 | en_US |
dc.identifier.scopusauthorid | Vanhoutte, PM=7202304247 | en_US |
dc.identifier.issnl | 0007-1188 | - |